Pasteur Institute

Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Retrieved on: 
월요일, 11월 7, 2022
Biotechnology, People with Disabilities, Health, FDA, Children, Genetics, Consumer, Clinical Trials, Patient, Company, European Commission, Hearing, Food, EMA, ODD, Huber loss, European Medicines Agency, Pasteur Institute, FDA, Cochlear Limited, Biomarker, Mutation, CIO, Trial of the century, Marketing, Congenital hearing loss, US Foods, Genetics, Deafness, Hearing loss, Diagnosis, AAV, CTA, Solution, Pharmaceutical industry, Dentistry, Medical device

Sensorions OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one of the most common forms of congenital deafness.

Key Points: 
  • Sensorions OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one of the most common forms of congenital deafness.
  • Patients with OTOF mutations suffer from severe to profound sensorineural prelingual non syndromic hearing loss.
  • The designation is another key piece in the puzzle that helps advance Sensorion towards clinical development in OTOF-GT in 2023.
  • The FDA grants Rare Pediatric Disease Designation for serious and life-threatening diseases that primarily affect children ages 18 years or younger and fewer than 200,000 people in the United States.

ABARCA PRIZE RECOGNIZES MEDICAL-SCIENTIFIC RESEARCH IN ITS 2ND EDITION, BY HM HOSPITALES

Retrieved on: 
금요일, 10월 28, 2022
Dysentery, Lists of countries and territories, Institut Pasteur Korea, Disease, Vaccine, Death, Rockefeller University, Shigella, Diarrhea, Multimedia, Shigellosis, Pasteur Institute, Research, CSIC, Cell biology, Scientific method, Medicine, WHO, Biology, Health, Pharmaceutical industry

The 'ABARCA PRIZE' award ceremony held in Madrid (Spain) brought together more than 130 guests and renowned public figures.

Key Points: 
  • The 'ABARCA PRIZE' award ceremony held in Madrid (Spain) brought together more than 130 guests and renowned public figures.
  • The ABARCA PRIZE is endowed with 100,000 euros and an accrediting diploma.
  • Professor Sansonetti said "It is an honor to be awarded the ABARCA PRIZE.
  • The 'ABARCA PRIZE' Award began in 2021 to highlight on the international stage the impact of medical-scientific advances and innovations.

Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Retrieved on: 
월요일, 10월 24, 2022
Research, People with Disabilities, Clinical Trials, Biotechnology, Managed Care, Pharmaceutical, Consumer, Health, Science, Oncology, Deafness, Union, Population, Diagnosis, EMA, Cisplatin, POC, Proof of concept, Pasteur Institute, Patient, Cancer, Neoplasm, Biomarker, Company, PTA, Hearing loss, Mutation, Incidence, Cochlear Limited, Adult, Ototoxicity, Genetics, Clinical trial, CIO, Hearing, FDA, Huber loss, Pharmaceutical industry, Dentistry

Approval has been granted to conduct a Phase 2a trial with SENS-401 in CIO.

Key Points: 
  • Approval has been granted to conduct a Phase 2a trial with SENS-401 in CIO.
  • Following extensive analysis of the AUDIBLE-S study data earlier in 2022, Sensorion has adapted the design of this trial to focus the prevention of hearing loss.
  • We are delighted to have received approval for our clinical trial recently amended with SENS-401, which we believe has the potential to preserve hearing for patients receiving cisplatin.
  • Sensorion currently develops SENS-401 in a Phase 2a clinical trial for the prevention of residual hearing loss in patients scheduled for cochlear implantation, and in a Phase 2 clinical trial for the prevention of Cisplatin-Induced Ototoxicity.

SpikImm, a Biotechnology Company Founded by Truffle Capital Under License from the Institut Pasteur, Announces that the Clinical Trials for SPK001, its Monoclonal Antibody Against SARS-COV-2, Have Begun

Retrieved on: 
목요일, 10월 20, 2022
Research, Infectious Diseases, Finance, Consulting, Clinical Trials, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Risk, Science, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, NASDAQ, Volunteering, Pasteur Institute, Patient, Antibody, Institut Pasteur Korea, Multimedia, Mortality, Partnership, MD, CBRN, Immunodeficiency, Disease, CEO, Research, Vaccination, COVID-19, Professor, Half-life, Hematological Cancer Research Investment and Education Act, Pharmaceutical industry, Vaccine, Omicron

SPK001 and SPK002 are among the most promising monoclonal antibodies against SARS-CoV2 in the world.

Key Points: 
  • SPK001 and SPK002 are among the most promising monoclonal antibodies against SARS-CoV2 in the world.
  • Depending on the results, SpikImm could seek early access and emergency use1 approval as early as the second quarter of 2023.
  • With its experienced team and its partnership with Institut Pasteur, SpikImm has a strong platform for accelerated antibody development to address emerging respiratory diseases.
  • SpikImm has recently been designated winner of the call for expressions of interest "Emerging Infectious Diseases and CBRN Threats, France 2030".

4Moving Biotech Announces First Patient Enrolled in Phase I Clinical Trial on Osteoarthritis

Retrieved on: 
금요일, 10월 14, 2022
Biotechnology, Managed Care, Other Health, Health, General Health, Pharmaceutical, Medical Devices, Research, Hospitals, Science, Clinical Trials, Quality of life, Liraglutide, Pasteur Institute, Patient, MBA, AP-HP, Trial of the century, Doctor of Philosophy, Adult, Safety, Clinical trial, CMO, OA, Rheumatology, Sorbonne University, Pharmaceutical industry, Osteoarthritis, Biotechnology, Biotechnology, Managed Care, Other Health, Health, General Health, Pharmaceutical, Medical Devices, Research, Hospitals, Science, Clinical Trials

4Moving Biotech, a biotechnology company and subsidiary of 4P-Pharma, focusing on the development of a first-in-class disease modifying osteoarthritis drug (DMOAD) for a curative treatment of osteoarthritis, announces that it has enrolled its first patient for phase I of LASARE clinical trial study.

Key Points: 
  • 4Moving Biotech, a biotechnology company and subsidiary of 4P-Pharma, focusing on the development of a first-in-class disease modifying osteoarthritis drug (DMOAD) for a curative treatment of osteoarthritis, announces that it has enrolled its first patient for phase I of LASARE clinical trial study.
  • "We are so excited to have the first patient enrolled in our first-in-human phase 1 clinical study.
  • More information about clinical trial: https://4p-pharma.com
    4Moving Biotech is a biotech start-up company focusing on the development of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD).
  • 4Moving Biotech is headed by Revital Rattenbach, PhD, MBA, founder, and chairwoman of 4P-Pharma and 4Moving Biotech, and Francis Berenbaum, co-founder and CEO/CMO of 4Moving Biotech, Professor of rheumatology at Sorbonne University and Head of rheumatology department at St-Antoines hospital (AP-HP) in Paris.

Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022

Retrieved on: 
목요일, 10월 6, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Doctor of Pharmacy, Deafness, ESGCT, Diagnosis, EMA, Cell, Pasteur Institute, Patient, Gene, MSC, European Society of Gene and Cell Therapy, Trial of the century, Company, Mutation, Hearing loss, Cochlear Limited, Genetics, CIO, Hearing, Autosome, ID, Biomarker, Pharmaceutical industry, Vaccine

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.

Key Points: 
  • Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.
  • Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies.
  • Sensorion pursues its broad strategic collaboration with Institut Pasteur focused on the genetics of hearing.
  • The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion to Participate in Various Upcoming Investor Conferences

Retrieved on: 
월요일, 9월 26, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Capital, Trial of the century, McDermott Will & Emery, Biomarker, CIO, Hearing loss, Company, Capital market, Hearing, Cochlear Limited, Patient, Genetics, List of life sciences, Deafness, Diagnosis, Pasteur Institute, Conference, Mutation, Pharmaceutical industry

Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of Sensorions management in various upcoming investor conferences.

Key Points: 
  • Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of Sensorions management in various upcoming investor conferences.
  • CEO Nawal Ouzren will attend, in-person, the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, in New-York, USA.
  • On this occasion, she will participate in a fireside chat and will be available for one-on-one meetings throughout the event.
  • CEO Nawal Ouzren will participate, in-person, in the HealthTech Innovation Days (HTID) meeting on October 13, 2022, in Paris, France.

Surge Raises $2.6M, Secures Exclusive Licensing Agreement with Stanford to Make Surgeries Safer

Retrieved on: 
금요일, 9월 23, 2022
Foch Hospital, Partner, Health, Boutique, Infection, Algorithm, Wilco, CyTOF, Stanford University School of Medicine, Risk, MD, Ferdinand Foch, StartX, Industry, Lists of diseases, Patient, Physician, Disease, Technology, Stanford University, Goal, Solution, Transparency (market), Doctor of Philosophy, Pasteur Institute, Dementia, SAN, Research, Ageing, Associate, Silicon, Hospital, Mortality, Hardware Club, Immune system, Plasma, AP-HP, Biotechnology, Medicine, Medical device, Pharmaceutical industry, Anesthesiology, Surge

SAN FRANCISCO, Sept. 23, 2022 /PRNewswire/ -- Biotech and medical AI innovator Surge announced a $2.6 million round co-led by HCVC, a global early-stage fund dedicated to high-potential technology startups, and Boutique Venture Partners, a leading fund based in the Silicon Valley. Veteran angel investors, including Nicolas Godin, the COO/CFO of Cardiologs, also participated in the round. Surge was awarded the 2022 iLab grant, along with other non-dilutive grants to complete the fundraising.

Key Points: 
  • Surge was awarded the 2022 iLab grant, along with other non-dilutive grants to complete the fundraising.
  • In the summer of 2022, Surge also signed a research agreement with Stanford with the goal of developing biotech innovations.
  • The burden of complications is increasing as the population ages and the number of surgeries increases almost 5% per year (Transparency Market Research).
  • "We are proud to support Surge in its ambition to reduce the risk of postoperative complications.

Sensorion Reports 2022 First Half Results

Retrieved on: 
목요일, 9월 22, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Adult, Presbycusis, Ototoxicity, POC, Platinum, CMC, Cisplatin, GLP, ODD, AAV, COMP, Control, FDA, Cochlea, Research, CIO, European Medicines Agency, GJB2, Thermo Fisher Scientific, European Commission, CTA, Company, Treasury, G7, Hearing loss, Perilymph, Huber loss, Partnership, Cancer, Chemistry, Patient, Clinical trial, CEO, The Association, Royal IHC, CDMO, Solution, G&A, Pasteur Institute, Committee, Association, Mali, Animal, EMA, OTOF, Association for Research in Otolaryngology, Pharmaceutical industry, Medical device, Dentistry, Vaccine, Fine chemical, Otorhinolaryngology

Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its half-year results as of June 30, 2022, alongside its outlook for the remainder of 2022.

Key Points: 
  • Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its half-year results as of June 30, 2022, alongside its outlook for the remainder of 2022.
  • Nawal Ouzren, CEO of Sensorion, said: Sensorion has made good progress across our pipeline of small molecule and gene therapy programs in the first half of this year.
  • In late 2021, Sensorion filed a proof-of-concept clinical trial application in CIO to evaluate the potential of SENS-401 treatment.
  • Following further analysis of the AUDIBLE-S study earlier in 2022, Sensorion has adapted the NOTOXIS trial design to focus SENS-401 in the prevention arm only.

Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Retrieved on: 
수요일, 9월 14, 2022
Research, Medical Devices, People with Disabilities, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Adult, Trial of the century, Huber loss, FDA, Food, Biomarker, Cochlea, CIO, Arm, Hearing loss, Company, Perilymph, Population, IND, Hearing, Cochlear Limited, Patient, Clinical trial, Genetics, Deafness, Diagnosis, Pasteur Institute, US, Investigational New Drug, US Foods, Cochlear, Mutation, Dentistry, Medical device, Pharmaceutical industry

At the beginning of 2021, Sensorion disclosed positive preclinical data demonstrating that the combination of SENS-401 alongside a cochlear implant helped reduce loss of residual hearing at a frequency located beyond the electrode array.

Key Points: 
  • At the beginning of 2021, Sensorion disclosed positive preclinical data demonstrating that the combination of SENS-401 alongside a cochlear implant helped reduce loss of residual hearing at a frequency located beyond the electrode array.
  • Preclinical studies were undertaken in collaboration with the global leader in implantable hearing, Cochlear Ltd.
    We are very pleased to commence this trial in collaboration with Cochlear, said Graldine Honnet, Chief Medical Officer of Sensorion.
  • With encouraging supporting preclinical data, we believe that SENS-401 has the potential to improve the preservation of residual hearing in patients receiving cochlear implants.
  • Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing.